Inhaled aztreonam
Copyright policy )Inhaled aztreonam
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.
- UMass Memorial Medical Center United States
- UMass Memorial Health Care United States
- University of Massachusetts Medical School United States
Cystic Fibrosis, Lysine, Respiratory Tract Diseases, Pediatrics, Anti-Bacterial Agents, Aztreonam, Treatment Outcome, Inhalation, Allergy and Immunology, Administration, Administration, Inhalation, Drug Discovery, Pseudomonas aeruginosa, Humans, Pseudomonas Infections, use
Cystic Fibrosis, Lysine, Respiratory Tract Diseases, Pediatrics, Anti-Bacterial Agents, Aztreonam, Treatment Outcome, Inhalation, Allergy and Immunology, Administration, Administration, Inhalation, Drug Discovery, Pseudomonas aeruginosa, Humans, Pseudomonas Infections, use
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).18 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!